N/A
Completed N=254
Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation
Pregnancy; Nutritional Diseases
Source: ClinicalTrials.gov NCT03310983 ↗
Enrolled (actual)
254
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcomePrimary: Infant Fat Mass (FM) — 3050.7; 3673.6 g
Summary
The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Infant Fat Mass (FM) |
3050.7; 3673.6 | — |
| SECONDARY Central Fat Mass |
1085.3; 1377.3 | — |
Eligibility Criteria
Participants for this study are invited from the parent study, ADORE. Eligibility listed reflects criteria for the ADORE study.
Inclusion Criteria
- Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA
- Available by telephone
Exclusion Criteria
- Expecting multiple infants
- Gestational age at baseline 20 weeks
- Unable or unwilling to agree to consume capsules until delivery
- Unwilling to discontinue use of another prenatal supplement with DHA that contains ≥ 200 mg DHA
- Women with allergy to any component of DHA product (including algae), soybean oil or corn oil
Data sourced from ClinicalTrials.gov (NCT03310983). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.